Pediatric TB Intensive San Antonio, Texas October 14, 2013
|
|
- Mildred Cole
- 5 years ago
- Views:
Transcription
1 Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following disclosures to make: Is a current member of the Data Safety Monitoring Board at Otsuka Pharmaceuticals & Roach. No relevant financial relationships with any commercial companies pertaining to this educational activity 1
2 DIRECTLY OBSERVED THERAPY FOR TUBERCULOSIS means a dispassionate 3rd party is actually present when medications are taken with every dose standard of care in U.S. for treating tuberculosis disease desirable for high risk infections - newborns and infants, household contacts, HIV - infected or immune compromised 2
3 DRUG RESISTANCE IN TUBERCULOSIS The development of drug resistance in M. tuberculosis is the result of a conspiracy among the organism, the patient, the doctor and the healthcare system! DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS genetic loci for resistance on chromosome, unlinked resistance of drugs independent frequency of mutations at loci is known more likely to have mutations when mycobacterial population is larger : infection vs. disease primary - resistance present when infection acquired secondary - resistance develops while on therapy 3
4 Preventing Drug Resistance in TB Cavity 10*9 organisms 10*3 R-INH 10*2 R-RIF All organisms R-RIF killed 10*3 organisms R-INH survive and grow Cavity 10*9 organisms All R-INH 10*2 R-RIF I INH R-INH: 10*-6 R-RIF: 10*-7 R-INH+RIF: 10*-13 Preventing Drug Resistance in TB Cavity 10*9 organisms RIF kills R-INH organisms 10*3 R-INH 10*2 R-RIF CURE! INH kills R-RIF organisms I INH + RIF R-INH: 10*-6 R-RIF: 10*-7 R-INH+RIF: 10*-13 4
5 Preventing Drug Resistance in TB Granulomas Granulomas 10*4-5 organisms? any R-INH? any R-RIF? Cure INH R-INH: 10*-6 R-RIF: 10*-7 R-INH+RIF: 10*-13 Treatment of Tuberculosis More bugs More drugs! 5
6 Roles of Specific TB Drugs in Regimens Isoniazid Bactericidal Prevents emergence of resistance to other drugs Rifampin Bactericidal Prevents emergence of resistance to other drugs Ethambutol Bacteriostatic at lower doses Prevents emergence of resistance to other drugs Pyrazinamide Allows for shorter durations of therapy Points To Ponder What is the real difference between TB infection and TB disease in children? The organism is present in both cases We can sometimes culture the organism from children with recent infection but no clinical disease We treat infection with 1 drug, disease with 3-4 drugs The functional difference is the burden of organisms Infection and disease are on a continuum when does infection turn into disease? The convention is that it is disease when we can see it with our eyes or feel it with our fingers 6
7 Susceptible TRANSITIONS IN TUBERCULOSIS Exposed Prevent Infection Infected Diseased Prevent Disease Sick Diagnosed Treated Curative Therapy Cured TUBERCULOSIS IN CHILDREN TREATING EXPOSED CHILDREN So-called window prophylaxis Very high rate of infection w/o treatment Takes up to 3 months for the skin test to turn positive U.S. studies 10% to 20% of childhood TB cases can be prevented if children exposed in a household receive isoniazid WHO standards children <5 years old in a TB household should be treated 7
8 Major Issues With Current Treatment Regimens for LTBI Acceptance Adherence and completion Self: 49% ESAT: 75% DOT: 98% Duration even 3 months is long Adverse events hepatotoxicity, hypersensitivity reactions Cost [beyond isoniazid] Drug-Drug interactions [esp. rifamycins] Misdiagnosis early TB disease Treatment of [Latent]Tuberculosis Infection Established therapies include: Isoniazid for 9 months Isoniazid for 6 months Rifampin for 4 months Isoniazid and rifampin for 3 months RIPE for 2 months [2 RZ] Isoniazid and rifapentine once weekly for 12 weeks [under directly observed therapy] 8
9 Sterling et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155. Rifapentine [15 mg/kg/dose] is a rifamycin with a long halflife and greater potency against M. tuberculosis A CDC-funded clinical trials group conducted an open label randomized non-inferiority trial ( ) comparing 3 months of once-weekly rifapentine [900 mg max.] plus isoniazid [900 mg max.] under DOT with 9 months of daily self-administered isoniazid [300 mg max.] in subjects at high risk for TB [case contacts or recent TST conversion] For initial enrollment, persons > 12 years of age Later enrollment of children 2 11 years of age Subjects followed for 33 months after enrollment Sterling et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365: enrolled and eligible subjects 87% of subjects completed 33 months f/u [mean 30] TB developed in 0.19% of subjects receiving combination therapy and 0.43% of isoniazid only subjects Among subjects who completed 100% of the doses, 5/3376 in the combination group and 6/2792 in the isoniazid group developed TB Treatment completion was higher in the combination [82%] than the isoniazid [69%] group Main adverse reaction: Combination: hypersensitivity Isoniazid: hepatitis 9
10 Sterling et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155. Sterling et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155. Jereb et al. MMWR 2011 (Dec.);60:1650 CDC recommends 12 weeks of once weekly DOT INH-RPT in otherwise healthy patients > 12 yrs of age who are at high risk for developing disease Children 2-11 yrs of age: Efficacy not adequately studied and safety and tolerability data not yet assessed The preferred regimen for children aged 2-11 years is 9 months of isoniazid. However, INH-RPT can be considered on a case-by-case basis when both 1) the circumstances make the completion of 9 months of isoniazid unlikely and 2) the likelihood or hazard of TB is great 10
11 Limitations and Advantages of the INH-RFP 12 Week, Once Weekly Regimen Limitations Lack of data in children < 12 years of age Must be given under DOT health departments to decide if, how and when they can gear-up No cost-benefit analysis Shortage of rifapentine Advantages 3 months vs. 9 months higher adherence, esp. in transient groups and individuals Less hepatitis high risk persons Perhaps more effective PEARLS OF WISDOM FOR TREATING LTBI IN CHILDREN Use INH suspension only in children 5 kg Use DOPT for: recent contacts, infants, immune compromised When children aren t tolerating INH, the problem is more often with the parent than the child Route LFTs only for: other liver toxic drugs, liver disease, signs or symptoms of hepatitis Pyridoxine needed only for breast-feeding infants, pregnancy, poor diets 11
12 Considerations for Pediatric TB Treatment Regimens Very few true RCTs have been performed for intrathoracic TB, almost none for extrapulmonary TB Regimens that work in adults tend to work in children; may define the maximum treatment children require However, adult data do not necessarily define the minimum treatment required by children Children generally tolerate existing drugs and drug regimens better than adults Therapy for TB Disease Start 4-drug therapy - RIPE INH, rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB); INH/RIF are the backbone of therapy Use PZA only during 1 st 2 months for susceptible TB This is your shortening agent : consolidate from 9 to 6 months of therapy Stop EMB once culture results known, if have pan-susceptible TB This is your insurance in case you have drug-resistant TB Anticipate minimum 6 month therapy, and we often extend it to longer periods, especially for extrapulmonary disease Always administered by directly observed therapy (DOT) 12
13 Ethambutol Metabolized faster by children than adults Same mg/kg dose results in lower serum levels in children Consequently, risk of optic neuritis is very low You can feel very comfortable using ethambutol even in the pre-verbal child in whom visual acuity screening is challenging! Remember, however, that it crosses the bloodbrain barrier poorly and should not be used for meningitis Regimen 1 for Treatment of Pulmonary, Drug-Susceptible TB 6 month standard regimen Initial phase INH, RIF, PZA, EMB daily (7 or 5 days/week) for 8 weeks Continuation phase options 1) INH, RIF daily (7 or 5 days/week) for 18 weeks 2) INH, RIF intermittently (2 days/week or 1 day/week for INH, RPT) for 18 weeks 13
14 Regimen 2 for Treatment of Pulmonary, Drug-Susceptible TB 6 month daily +intermittent options Initial phase INH, RIF, PZA, EMB daily (7 or 5 days/week) for 2 weeks, then 2 days/week for 6 weeks Continuation phase INH, RIF intermittently (2 days/week) for 18 weeks Regimen 3 for Treatment of Pulmonary, Drug-Susceptible TB 6 month intermittent dosing options Initial phase INH, RIF, PZA, EMB intermittently (3 days/week) for 8 weeks Continuation phase INH, RIF intermittently (3 days/week) for 18 weeks 14
15 Regimen 4 for Treatment of Pulmonary, Drug-Susceptible TB 9 month without pyrazinamide options Initial phase INH, RIF, EMB daily (7 or 5 days/week) for 8 weeks Continuation phase options 1) INH, RIF daily (7 or 5 days/week) for 31 weeks 2) INH, RIF intermittently (2 days/week) for 31 weeks WHO Rapid Advice 2010 Pulmonary and Lymph Node TB in Children Standard therapy is 2HRZE + 4HR Where prevalence of HIV and INH resistance are low, therapy can be 2HRZ+4HR In HIV uninfected children with fully drug-susceptible TB, thrice weekly regimens can be used in the continuation phase with well established DOT [Weak recommendation, very low-quality evidence] Children with HIV infection should not receive intermittent regimens [Strong recommendation, lowto-moderate quality evidence] 15
16 WHO Rapid Advice 2010 Meningeal and Osteoarticular TB Children with suspected or confirmed tuberculous meningitis should be treated with HRZE for 2 months, followed by HR for 10 months, the total duration of therapy being 12 months. Standard doses should be used. [Strong recommendation, low-quality evidence] Children with suspected or confirmed osteoarticular tuberculosis should be treated with HRZE for 2 months followed by HR for 10 months, the total duration of therapy being 12 months. Standard doses should be used. [Strong recommendation, low-quality evidence] Notes on TB Drugs Drug Side Effects Other notes INH RIF PZA EMB Peripheral neuropathy; seizures in overdose; hepatotoxicity Orange discoloration of secretions; inactivates oral contraceptives; many drug interactions; hepatotoxicity Can increase uric acid gout symptoms; rash; pruritis; hepatotoxicity Optic neuritis, red-green color blindness B6 helps prevent neuropathy and is only treatment for INH seizures, but doesn t prevent hepatotoxicity Please warn of orange urine! Of 1 st -line drugs, greatest association with hepatotoxicity Despite side effects, has very poor CNS penetrance and not used for meningitis 16
17 Medication Tolerance Pediatrics: 5% risk of side effects in children Most minor abdominal pain without elevation in LFTs 3.3% incidence of elevated LFTs with INH and Rifampin (usually asymptomatic) Peripheral neuropathy quite rare before adolescence Adults: Hepatotoxicity: 3-4% with INH alone Up to 5% with INH and Rifampin Peripheral neuropathy: 4% Bone marrow suppression: 2% Medication Administration INH suspension only to child not taking any solid/pureed foods Warn parents about rifampin and urine color Make sure child can tolerate all medication doses prior to discharge (for some young babies, doses may need to be divided in the course of the day) 17
18 FOLLOW-UP EVALUATIONS FOR CHILDREN WITH TUBERCULOSIS skin test stays positive forever frequent chest xrays unnecessary - at diagnosis, 1-2 months, end of therapy follow growth & development closely adequate nutrition routine liver enzyme monitoring not necessary routine vitamin B 6 not necessary except breastfeeding, pregnant adolescents, poor diet CORTICOSTEROIDS IN PEDIATRIC TUBERCULOSIS Useful when host inflammatory response is contributing to tissue damage or dysfunction meningitis endobronchial miliary with alveolar block pericardial with constriction vertebral with spinal root irritation Can use prednisone or dexamethasone 18
19 19
20 Treatment of Drug Resistant TB in Children INH mono-resistance: well-treated with 6-9 months of rifampin, pyrazinamide and ethambutol MDR- TB: treatment must be individualized depending on Exact drug susceptibility profile Anatomic location of disease Extent of disease Tolerance of medications Requires 4-6 drugs to which the organism is susceptible, at least 2 being bactericidal Recommended Monitoring While on Treatment Major obstacles to treating pediatric MDR TB is keeping children on numerous medications for a prolonged period. Many of these medications have side effects that need to be closely monitored. Close monitoring of side effects, and treating those side effects or changing medications when necessary can greatly improve adherence. Recent studies have shown that children often tolerate MDR-TB regimens better than adults
21 All Children Baseline Month Ongoing HIV status X Toxicity symptoms X X X X X X X X X X X X Height and weight X X X X X X X X X X X X Audiology (while on injectable) X X X X X X X Color vision testing (if on ethambutol) Recommended Drug Monitoring Schedule Chest X-ray (if lung involvement) X X X X X X X X X X X X X X X TB culture and DST X X X X X X X X X X X Creatinine and potassium X X X X X X X TSH/T4 (If on prothionamide, ethionamide, or PAS) X X X X X X X X Blood count with diff (If HIV positive or on linezolid) X X X X X X X X X X HIV-infected children LFT s, cholesterol (if on ART) X X X X Adverse Event Hepatotoxicity Likely Culprit Drugs INH, RIF, PZA, ethionamide, PAS, clofazimine Adverse Effects Identification Tender liver, visible jaundice Management Stop all drugs; Wait for liver function to return to normal; Reintroduce drugs one-byone, every 2 days with monitoring of liver function before next drug Visual Problems EMB, ethionamide, PAS, linezolid Regular testing Stop EMB or substitute alternative drug; offer B6 with ethionamide Hearing Problems Amikacin, capreomycin, kanamycin Identification through audiometry or problems in communication Consider stopping injectable drug, substituting alternative drug, reducing dose or increasing dosing interval 21
22 Adverse Event Likely Culprit Drugs Adverse Events Identification Management Thyroid dysfunction Ethionamide, PAS Regular blood testing, clinical hypothyroidism or goiter Consider thyroxine supplementation (0.5g daily) if clinical hypothyroidism or raised TSH and decreased ft4 If raised TSH or decreased ft4 repeat test in one month Renal impairment Amikacin, capreomycin, kanamycin Regular blood testing, symptoms of high potassium If creatinine rises or if potassium is high, stop injectable, substitute for alternative drug, dose 3 times per week or reduce dose Severe Rash Any drug, skin discoloration (clofazimine), cycloserine, linezolid, EMB, STM Severe rash, peeling mucous membranes, child unwell Stop all drugs; Wait until clinical condition improves; Reintroduce drugs one by one, every 2 days, monitor closely Adverse Events Adverse Event Likely Culprit Drugs Identification Management Nausea and vomiting INH, RIF, EMB, PAS, ethionamide, PZA, clofazimine Clinically Considering separating the dosing of THA from the other drugs, by giving it in the evening; Consider reducing the dose of THA and building the dose back up to full dose over 2 weeks Diarrhea PAS Clinically Split dose of granules to give small doses throughout the day, Reduce dose, Consider loperamide Peripheral neuropathy INH, ethionamide, fluoroquinolones, linezolid, EMB, cycloserine, injectables Clinically Give or increase pyridoxine; If persistent or sever, stop INH 22
23 Adverse Event Likely Culprit Drugs Adverse Events Identification Management Neuropsychiatric problems INH, ethionamide, fluoroquinolones, terizidone, cycloserine Seizures, headache, behavior changes, sleep disturbances Verify correct dosing; Stop likely culprit drug; If symptoms persist, reintroduce and stop next most likely dose Less with terizidone than cycloserine Joint problems PZA, ofloxacin, levofloxacin, moxifloxacin Clinically Verify correct dosing; Consider reducing dose or stopping possible culprit drug; Consider trial of allopurinol Painful injection sites Amikacin, capreomycin, kanamycin Clinically Add local anesthetic to drug in equal volumes; Vary site of injection on a daily basis, If severe, consider splitting dose and giving half into two different sites Warm packs to skin Adverse Events Adverse Event Bone marrow suppression Likely Culprit Drugs PAS, rifampin, cycloserine (anemia), linezolid Identification Regular blood testing, ecchymoses Management PAS: B12 supplementation Cycloserine: folate supplementation Severe cases: G-CSF Arrhythmia Fluoroquinolones Baseline EKG Correct hypokalemia, hypomagnesemia; beware use of quinolones with other medications which can prolong the QTc 23
24 Potential Drug Interactions Drug 1 Drug 2 Symptom Management Ethionamid e Cycloserin e Increase seizure risk Consider checking levels Ethionamid e INH Increased seizure risk Pyridoxine Clofazimine INH INH increases clofazimine serum and decreases skin concentration Unclear clinical significance Clofazimine RIF Clofazimine results in decreased rifampin concentrations Unclear clinical significance PAS RIF Decreased RIF concentrations Unclear clinical significance Strategies to Lessen AEs Separate medication over time Provide potential nausea-inducing medicine (e.g., ethionamide) separately from other medications Provide medication to children with food Educate caregivers on what side effects are seen with medications, as well as what symptoms would not be consistent with a medication AE 24
At the end of this session, participants will be able to:
Advanced Concepts in Pediatric TB: Treatment of Tuberculosis Disease Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [with help from Andrea Cruz, M.D.] Objectives At the end
More informationPediatric TB Intensive Houston, Texas
Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTreatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27
TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationTreatment and Monitoring
Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationOfficial ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016)
Official ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (Nahid et al, CID 2016) APPENDIX C: DRUGS IN CURRENT USE The U.S. Food and Drug Administration (FDA) has approved
More informationDisclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t
Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations
More informationManagement of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationLTBI in Special Populations John Nava, MD October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John
More informationTB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects
TB Nurse Case Management San Antonio, TX April 1 3, 2014 TB Medications and Adverse Effects Debbie Onofre RN, BSN Nurse Consultant/ Nurse Educator Heartland National TB Center April 1, 2014 Debbie Onofre,
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationTuberculosis medications: adverse drug reactions
Tuberculosis medications: adverse drug reactions Rajesh M. Prabhu, M.D. Infectious Diseases Essentia Health, Duluth, MN July 25, 2017 2014 MFMER slide-1 No Finanial Disclosures Learning Objectives 1. Describe
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationDrug Side Effects and Toxicity
Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationTreatment of Tuberculosis
Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Managing Anti-TB Therapy Side Effects and Complications Lisa Armitige, MD, PhD May 9, 2012 Lisa Armitige, MD, PhD has the following
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationTB in the Correctional Setting Florence, Arizona October 7, 2014
TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationPediatric Tuberculosis: The Essentials October 8, 2014
Pediatric Tuberculosis: The Essentials Ann M Loeffler, MD Randall Children s Hospital at Legacy Emanuel Portland, Oregon Curry International TB Center Disclosures Nothing to disclose Learning Objectives
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
More informationDRUG SIDE EFFECTS AND TOXICITY
DRUG SIDE EFFECTS AND TOXICITY Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Objectives After participating in this lecture,
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationManagement of MDR TB in special situations. Dr Sarabjit Chadha The Union
Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationTreatment of Tuberculosis
Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:
More informationClinical Trials Lecture 4: Data analysis
Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis
More informationTB Nurse Case Management
TB Nurse Case Management San Antonio, Texas March 2-4, 2011 TB Medications and Adverse Effects Debbie Onofre, RN, BSN March 3, 2011 Debbie Onofre, RN, BSN has the following disclosures to make: No conflict
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationManaging and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Iris Barrera, RN April 11, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Iris Barrera,
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationTreatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1
Treatment of Tuberculosis Some Highlights of Most Recent Update Treatment of Tuberculosis Disease Germaine Jacquette, MD Physician Specialist NJMS Global Tuberculosis Institute September 15, 2010 The provider
More informationTB Intensive San Antonio, Texas August 7-10, 2012
TB Intensive San Antonio, Texas August 7-10, 2012 An Introduction to Childhood Tuberculosis Kim Smith, MD, MPH August 10, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationTreatment of Tuberculosis
Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationPharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationAntituberculous Agents
Antituberculous Agents Primary or First Line Drugs: Isoniazid (INH) Rifampin Rifadin or Rimactane Ethambutal Streptomycin Pyrazinamide Isoniazid(INH) Most active. Small molecule, water soluble, Structurally
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationCLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has
More informationTB Drugs. Discuss the common route for transmission of the disease. Discusses the out line for treatment of tuberculosis.
TB Drugs Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Females doctor notes Grey: Males doctor notes OBJECTIVES: By the end of this lecture,
More informationOvercoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
More informationDisclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis.
More information